CJC-1295 vs Sermorelin: Two GHRH Analogues, One Family Tree and a Very Different Clock

Both of these peptides trace their ancestry back to the same unlikely place: a tumour. In the early 1980s, two rival teams at the Salk Institute in California finally isolated the hormone the brain uses to tell the pituitary gland to release growth hormone, not from a brain, but from pancreatic tumours that had caused acromegaly in their patients. Every growth hormone releasing hormone analogue studied today, Sermorelin and CJC-1295 included, descends from that discovery.

Yet the two could hardly behave more differently. One is gone from the bloodstream in minutes. The other, in its DAC form, lingers for around a week. That single difference in timing shapes almost everything about how researchers use them. This guide explains where each came from, how they are built, what the human studies measured, and how to decide which suits a particular research question. Both compounds are supplied by Crown Peptides for laboratory research use only.

The Hormone Hunt That Ended in a Pancreas

By the 1970s, scientists knew that the hypothalamus, a small region at the base of the brain, controlled the pituitary gland through a set of releasing hormones. Roger Guillemin and Andrew Schally shared the 1977 Nobel Prize in Physiology or Medicine for identifying several of them. But the one that switched on growth hormone release refused to be found. It existed in hypothalamic tissue in such vanishingly small amounts that isolating enough to sequence seemed almost impossible.

The breakthrough came from medicine rather than neuroscience. Doctors had noticed a handful of patients with acromegaly, the condition of excess growth hormone that enlarges hands, feet and facial features, whose pituitary glands were not the problem. Instead, they had tumours elsewhere in the body, including the pancreas, that were churning out a growth hormone releasing substance. Those tumours were, in effect, factories producing far more of the elusive hormone than any brain ever would.

Two teams, one finish line

In November 1982, Guillemin’s group published the structure of a 44-amino-acid peptide isolated from a human pancreatic tumour that had caused acromegaly (PMID: 6812220). They synthesised it and showed that the synthetic version had full biological activity, specifically stimulating growth hormone secretion. They also noted it behaved just like the still-uncharacterised factor present in hypothalamic extracts. Wylie Vale’s team, also at the Salk Institute, published a related 40-residue form from another pancreatic tumour at almost the same time.

That 44-amino-acid peptide is growth hormone releasing hormone, usually shortened to GHRH. It is the parent molecule of both compounds in this article.

The discovery that made analogues possible

Researchers quickly found something extremely useful: the whole 44-amino-acid chain was not needed. The first 29 amino acids, counted from the start of the chain, carried essentially all of the hormone’s biological activity. That shorter fragment, written as GHRH(1-29) or GRF(1-29), became the foundation for everything that followed. Sermorelin is that fragment. CJC-1295 is a heavily engineered version of it.

What Is Sermorelin?

Sermorelin is a synthetic copy of the first 29 amino acids of human GHRH, with the end of the chain amidated to match the natural hormone. In other words, it is the shortest fully active fragment of the real thing, with no structural changes. It binds to the GHRH receptor on specialised cells in the anterior pituitary, called somatotrophs, and prompts them to release growth hormone.

The peptide that actually became a medicine

Sermorelin has a distinction that few research peptides share: it completed clinical development and was approved by the US Food and Drug Administration. Sold under the brand name Geref by Serono, it was first approved on 28 December 1990 as a diagnostic agent, used to test whether a child’s pituitary could release growth hormone. On 26 September 1997, a second approval followed for treating growth hormone deficiency in children with growth failure.

A 1999 review in BioDrugs by Prakash and Goa summarised the clinical picture at the time (PMID: 18031173). A single intravenous sermorelin test offered a rapid and relatively specific diagnostic test, producing fewer false positives in children without growth hormone deficiency than other provocative tests. Once-daily sermorelin produced significant and sustained increases in height velocity over 12 months in prepubertal children with idiopathic growth hormone deficiency, and induced catch-up growth in the majority. The most commonly reported side effects were transient facial flushing and injection site discomfort.

Why it disappeared from pharmacy shelves

Geref was voluntarily withdrawn by its manufacturer around 2008. In a Federal Register notice published in March 2013, the FDA formally determined that Geref was not withdrawn from sale for reasons of safety or effectiveness. That determination matters, because it opened the door for generic versions to reference the original approval. The withdrawal was a commercial decision, not a verdict on the molecule.

What the clinical years taught researchers

Sermorelin’s time as a licensed medicine left behind something research compounds rarely have: years of structured clinical observation. Three lessons from that record still shape how GHRH analogues are studied.

The pituitary has to be able to answer

The BioDrugs review noted an important limitation of the diagnostic test: a normal growth hormone response to sermorelin cannot rule out deficiency caused by a problem in the hypothalamus rather than the pituitary. That makes perfect biological sense. Sermorelin bypasses the hypothalamus and speaks directly to the pituitary, so a healthy pituitary will respond even if the brain’s own GHRH signal is missing. It is a neat illustration of exactly where in the axis a GHRH analogue acts.

Timing and frequency matter

In the paediatric studies, several administration schedules were explored, and height velocity responses varied between them. Evening administration was chosen to coincide with the large natural growth hormone pulse of early sleep. That focus on matching the body’s own rhythm is exactly the question CJC-1295’s designers later approached from the opposite direction, by extending the signal rather than timing it.

Stimulating the pituitary is not the same as replacing its hormone

The same review observed that increases in height velocity with sermorelin were smaller than those seen with direct growth hormone in the regimens compared. For researchers, that difference is the point rather than a drawback: a GHRH analogue works through the body’s own release machinery and feedback loops, which is precisely what makes it a useful tool for studying that machinery.

What Is CJC-1295?

CJC-1295 started with the same 29-amino-acid fragment and asked a very practical question: how do you stop it disappearing so fast?

Native GHRH and Sermorelin have extremely short lives in the bloodstream, measured in minutes. One of the main reasons is an enzyme called dipeptidyl peptidase-4, or DPP-4, which snips off the first two amino acids of the chain and inactivates it. Other enzymes attack elsewhere along the sequence. Then the kidneys clear what remains. A molecule that is gone in minutes is excellent for mimicking a natural pulse, but it limits how long any effect can last.

Four changes to the chain

CJC-1295 was developed by the Canadian biotech company ConjuChem. Its designers made four amino acid substitutions to the GRF(1-29) backbone: a D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27. Each targets a known weak point. The D-alanine at position 2, a mirror-image form of the amino acid, blocks DPP-4 from recognising its cutting site. The others improve resistance to other enzymes and reduce vulnerability to chemical degradation.

That modified 29-amino-acid peptide, on its own, is often called modified GRF(1-29) or CJC-1295 without DAC. It lasts meaningfully longer than Sermorelin but still acts over a relatively short window. It is the form found in our CJC-1295 (No DAC) + Ipamorelin (Blend).

The Drug Affinity Complex

ConjuChem’s signature idea was the Drug Affinity Complex, or DAC. This is a chemically reactive group attached to an added lysine at the end of the peptide. Once the peptide enters circulation, the DAC forms a covalent bond with albumin, the most abundant protein in blood. Albumin itself lasts for weeks, and a peptide attached to it is shielded from both enzymes and the kidneys. The result is a GHRH analogue that remains active for days rather than minutes.

The full differences between the DAC and non-DAC forms are covered in depth in CJC-1295 with DAC vs without DAC. In this article, “CJC-1295” refers to the DAC version unless stated otherwise.

What the Human Studies of CJC-1295 Found

CJC-1295 was tested in two published clinical studies in healthy adults, and both showed that a single injection can raise growth hormone and IGF-1 for days. They are worth knowing in detail.

A single injection, a week of effect

In 2006, Teichman, Frohman and colleagues published the results of two randomised, placebo-controlled, double-blind ascending-dose trials in the Journal of Clinical Endocrinology and Metabolism (PMID: 16352683). Healthy participants aged 21 to 61 received either CJC-1295 or placebo by subcutaneous injection, as single doses in the first trial and as two or three weekly or fortnightly doses in the second.

The results were striking. After a single injection, mean growth hormone concentrations rose dose-dependently by 2 to 10 times and stayed elevated for 6 days or more. Mean IGF-1 concentrations, the downstream marker that growth hormone drives in the liver, rose 1.5 to 3 times and stayed elevated for 9 to 11 days. The estimated half-life of CJC-1295 was 5.8 to 8.1 days. With multiple doses, IGF-1 remained above baseline for up to 28 days, with evidence of a cumulative effect. No serious adverse reactions were reported in these trials, and the authors described the compound as relatively well tolerated.

The pulse survives

That result raised an obvious question. Growth hormone is naturally released in pulses, with large bursts, particularly during deep sleep, separated by quiet periods. Many of its physiological effects are thought to depend on that pulsing pattern. Would a week-long GHRH signal flatten the rhythm into a constant drip?

Ionescu and Frohman tested exactly that in a follow-up study, also published in 2006 in the Journal of Clinical Endocrinology and Metabolism (PMID: 17018654). They took blood every 20 minutes across a 12-hour overnight period in healthy men aged 20 to 40, before and one week after a single injection of CJC-1295.

The pulses remained. The frequency and size of growth hormone secretory bursts were unchanged. What changed was the floor between them: trough growth hormone levels rose 7.5-fold. Mean growth hormone rose by 46% and IGF-1 by 45%. The authors concluded that CJC-1295 increased overall growth hormone and IGF-1 while preserving pulsatility, and they highlighted the rise in trough levels as a key mechanism behind the IGF-1 increase.

Where development went next

ConjuChem went on to explore CJC-1295 in further clinical settings, but the compound did not complete development as a licensed medicine. It remains one of the most thoroughly characterised GHRH analogues in the published literature, which is a large part of why it is so widely used in research.

CJC-1295 vs Sermorelin: The Differences That Matter

With the background in place, the comparison becomes clear. The two compounds share a target and an ancestor. They differ in structure, lifespan and the pattern of signal they deliver.

Structure

Sermorelin is the unmodified GHRH(1-29) fragment. CJC-1295 is GRF(1-29) with four amino acid substitutions and, in its DAC form, an extra lysine carrying the albumin-binding group. Sermorelin is the more natural sequence. CJC-1295 is the more engineered one.

Lifespan

This is the headline difference. Sermorelin is cleared within minutes, much like native GHRH. CJC-1295 with DAC has a measured half-life of roughly six to eight days in humans. CJC-1295 without DAC sits between the two, lasting longer than Sermorelin thanks to its enzyme-resistant substitutions but far shorter than the DAC version.

Signal pattern

Sermorelin produces a short, sharp stimulus, closely imitating a single natural GHRH pulse. CJC-1295 with DAC produces a sustained background of GHRH receptor activation over days, which the Ionescu study showed raises the baseline between natural pulses while leaving the pulses themselves intact. These are two genuinely different experimental tools, which is why the “which is better” question does not have one answer.

Regulatory history

Sermorelin completed development and was an FDA-approved medicine for children for well over a decade. CJC-1295 was tested in early clinical studies but never licensed. For researchers, that means Sermorelin brings a long clinical track record in paediatric settings, while CJC-1295 brings detailed pharmacokinetic data on a long-acting design.

Research literature

Sermorelin’s literature is older and heavily focused on paediatric growth hormone deficiency and diagnostic testing, with a later body of work on adult and ageing-related growth hormone decline, including a 2006 commentary in Clinical Interventions in Aging exploring it as an approach to adult-onset growth hormone insufficiency (PMID: 18046908, PMC2699646). CJC-1295’s literature is smaller but centred on the pharmacology of sustained GHRH signalling.

Choosing Between Them for a Research Question

Autocomplete data shows people asking whether Sermorelin or CJC-1295 is better, whether they are the same, and whether they can be used together. In research terms, the right answer depends entirely on what you are trying to find out.

When Sermorelin fits

Sermorelin is the natural choice when the research question is about the physiological GHRH pulse itself, how the pituitary responds to a single, native-like signal, how that response changes with age or other conditions, or how it compares with historical clinical data. Its unmodified sequence also makes it the purest tool for studying the GHRH receptor as it evolved to be stimulated.

When CJC-1295 with DAC fits

CJC-1295 with DAC suits questions about sustained GHRH receptor activation, raised baseline growth hormone, IGF-1 dynamics over days and weeks, and the effects of long-acting peptide design. Its well-characterised half-life also makes it valuable in studies of albumin-binding technology as a general drug design approach.

When CJC-1295 without DAC fits

The non-DAC form offers a middle ground: a more stable, enzyme-resistant peptide that still acts over a relatively short window, making it well suited to studying pulses with a more durable molecule. It is very frequently paired with Ipamorelin, for reasons explained below.

Can they be studied together?

Because Sermorelin and CJC-1295 act on the same receptor, combining them in the same experiment would mostly add more of the same signal rather than a new one. Researchers interested in combinations more commonly pair a GHRH analogue with a compound acting through a different receptor entirely: the ghrelin receptor.

The Technical Breakdown: Two Receptors, One Pituitary

To understand why GHRH analogues are so often studied alongside other peptides, it helps to look at the pituitary cell itself. This section goes a little deeper into the biology.

The GHRH receptor

Somatotroph cells in the anterior pituitary carry GHRH receptors, which belong to the class B family of G protein-coupled receptors. When GHRH, Sermorelin or CJC-1295 binds, the receptor activates a Gs protein, which switches on the enzyme adenylyl cyclase and raises levels of the messenger molecule cyclic AMP inside the cell. Cyclic AMP activates protein kinase A, which does two main things: it promotes the release of growth hormone already stored in the cell, and over time it increases production of new growth hormone and supports the growth of somatotroph cells themselves.

The ghrelin receptor

The same cells also carry a second receptor, the growth hormone secretagogue receptor, whose natural partner is ghrelin, a hormone produced mainly in the stomach. Compounds such as Ipamorelin, GHRP-2 and GHRP-6 act here. This receptor works through a different signalling route, raising intracellular calcium via the phospholipase C pathway, and it also acts at the hypothalamus to reduce somatostatin, the hormone that puts the brakes on growth hormone release.

Why the pairing makes sense

Because the two receptors use different internal signalling routes, stimulating both at once has been shown in the broader literature to produce a larger growth hormone release than either alone, a synergistic effect. That is the scientific logic behind the popularity of combinations such as the CJC-1295 (No DAC) + Ipamorelin (Blend), which we cover in CJC-1295 No DAC and Ipamorelin: the two-pathway approach.

The somatostatin brake and IGF-1 feedback

One reason GHRH analogues are considered physiological tools is that they leave the body’s feedback controls in place. Growth hormone stimulates IGF-1 production, and both growth hormone and IGF-1 feed back to the hypothalamus and pituitary to increase somatostatin and dampen further release. A GHRH analogue can only push a pituitary that is able to respond, and within the limits those brakes allow. That is a fundamental difference from supplying growth hormone directly.

Why Sequence Accuracy Matters So Much for These Peptides

Sermorelin is 29 amino acids long. CJC-1295 with DAC is 30, plus its albumin-binding group. At that length, peptide synthesis involves around 30 separate coupling steps, each of which must work almost perfectly. Any failures produce deletion sequences that differ from the target by a single amino acid and can sit very close to the main peak in an HPLC analysis.

For CJC-1295, accuracy has an extra dimension. The four substitutions are the whole point of the molecule. A version with a normal L-alanine at position 2 instead of D-alanine would have the same mass but lose its protection against DPP-4. And the DAC group itself must be intact and correctly attached for the albumin-binding mechanism to work. This is one of the clearest cases in the research catalogue where identity confirmation matters as much as purity.

The Crown Peptides standard

Every batch of Sermorelin, CJC-1295 with DAC and the CJC-1295 (No DAC) + Ipamorelin (Blend) supplied by Crown Peptides comes with a batch-specific certificate of analysis. HPLC confirms purity by separating the target peptide from related impurities, and mass spectrometry confirms the molecular mass matches the expected structure. Published certificates are available on our Lab Reports page, and our guide to reading a certificate of analysis explains what each figure means.

Handling longer peptides

Both peptides are supplied lyophilised and should be stored cold and dry. Longer peptides can take a little longer to dissolve and benefit from gentle swirling rather than shaking. Our guides to peptide reconstitution and peptide half-life are particularly relevant here, given how different the two compounds’ lifespans are. Bacteriostatic Water is available alongside them.

Related Compounds in the Growth Hormone Axis

CJC-1295 and Sermorelin sit within a wider family of compounds studied for their effects on the growth hormone axis. If you are researching one, these are the neighbours you will meet.

Tesamorelin

Tesamorelin is the third major GHRH analogue. Where Sermorelin keeps 29 amino acids and CJC-1295 modifies them, Tesamorelin keeps all 44 amino acids of full-length GHRH and adds a trans-3-hexenoyl group at the front to protect it from enzymes. It is the only one of the three currently approved as a medicine in the US, for reducing excess abdominal fat in HIV-associated lipodystrophy. Our comparison Sermorelin vs Tesamorelin explores that pairing.

Ipamorelin

Ipamorelin is a five-amino-acid ghrelin receptor agonist known for its selectivity: in published research it stimulates growth hormone release with minimal effect on cortisol and prolactin. It is the most common partner for GHRH analogues. See Tesamorelin vs Ipamorelin and our Ipamorelin guide.

GHRP-2 and GHRP-6

GHRP-2 and GHRP-6 are earlier ghrelin receptor agonists. GHRP-2 is notably potent and, like Sermorelin, has been used as a diagnostic agent in clinical medicine. GHRP-6 is known for its pronounced effect on appetite signalling. Their differences are set out in GHRP-2 vs GHRP-6.

IGF-1 LR3

Downstream of the whole axis sits IGF-1. IGF-1 LR3 is a long-acting analogue of IGF-1 itself, used to study the effects of the axis at the tissue level rather than at the pituitary.

For the full set, browse our endocrine and hormonal research peptides and musculoskeletal research peptides categories.

Questions Researchers Ask About CJC-1295 and Sermorelin

Is Sermorelin the same as CJC-1295?

No. Both are based on the first 29 amino acids of GHRH, but Sermorelin is the unmodified fragment while CJC-1295 carries four amino acid substitutions and, in its DAC form, an albumin-binding group that extends its half-life from minutes to days.

Is Sermorelin the same as HGH?

No. Human growth hormone is a 191-amino-acid protein produced by the pituitary. Sermorelin is a 29-amino-acid peptide that signals the pituitary to release its own growth hormone. They act at entirely different points in the axis.

Is Sermorelin the same as Tesamorelin?

They are both GHRH analogues, but Tesamorelin uses the full 44-amino-acid sequence with a stabilising chemical group, while Sermorelin uses only the first 29 amino acids with no modification.

Which has more published human data?

Sermorelin, by a wide margin, thanks to its years as an approved paediatric medicine and diagnostic agent. CJC-1295’s human data comes mainly from the two 2006 studies described above, which are notable for their detailed pharmacokinetic measurements.

Why is CJC-1295 often sold without DAC in blends?

Because the non-DAC form acts over a shorter window that pairs naturally with a pulse-style ghrelin receptor agonist such as Ipamorelin, keeping the combined signal closer to a natural release pattern.

Same Ancestor, Different Futures

It is remarkable how much research has grown from a pair of pancreatic tumours studied in California four decades ago. Sermorelin took the discovery almost literally, trimming GHRH to its essential 29 amino acids and carrying that simple fragment all the way to FDA approval. CJC-1295 took the same fragment and re-engineered it, blocking the enzyme that destroys it and chaining it to albumin so that one molecule could keep signalling for a week, all without silencing the natural pulse.

Neither is simply better. One is a faithful copy of the body’s own signal. The other is a demonstration of what peptide engineering can do with it. For researchers, having both means being able to ask sharper questions about the growth hormone axis than ever before. Explore Sermorelin, CJC-1295 with DAC and the CJC-1295 (No DAC) + Ipamorelin (Blend), each batch HPLC and mass spectrometry verified and dispatched from the UK.